ストックスクリーナーアプリを入手
1.21
7.63%
-0.10
プレマーケット:
1.20
-0.01
-0.83%
前日終値:
$1.31
開ける：
$1.33
24時間の取引高:
371.36K
Relative Volume:
0.65
時価総額：
$76.65M
収益：
$9.53M
当期純損益:
$-44.61M
株価収益率:
-1.3297
EPS:
-0.91
ネットキャッシュフロー:
$-38.32M
1週間 パフォーマンス:
-0.82%
1か月 パフォーマンス:
+19.80%
6か月 パフォーマンス:
+58.94%
1年 パフォーマンス:
-56.79%
1日の値動き範囲:
$1.17
$1.33
1週間の範囲:
$1.17
$1.3635
52週間の値動き範囲:
$0.45
$2.93
Cue Biopharma Inc Stock (CUE) Company Profile
CUE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
1.21 | 76.65M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-13 | 開始されました | Jefferies | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2022-11-21 | 開始されました | Piper Sandler | Overweight |
| 2022-01-13 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-03 | 開始されました | Craig Hallum | Buy |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-04-09 | 開始されました | Stifel | Buy |
| 2020-01-28 | 開始されました | BTIG Research | Buy |
| 2020-01-22 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Cue Biopharma Inc (CUE) 最新ニュース
Geode Capital Management LLC Increases Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
HPV16+ Cancer Clinical and Non-Clinical Studies, Key - openPR
Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Up 8.0% in December - MarketBeat
Cue Biopharma (NASDAQ:CUE) versus FibroGen (NASDAQ:FGEN) Head-To-Head Comparison - Defense World
Certain Common Stock of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2024. - Marketscreener.com
Cue Biopharma CEO Daniel Passeri buys $30,900 in stock By Investing.com - Investing.com Australia
Cue Biopharma CEO Daniel Passeri buys $30,900 in stock - Investing.com India
Insider Buying: Daniel Passeri Acquires 30,000 Shares of Cue Bio - GuruFocus.com
Cue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in Stock - MarketBeat
Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5% - MarketBeat
Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus sparks debate - Investing.com
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Cue Biopharma Grants 200,000 Share Option Award to New Development Chief - StockTitan
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Strong week for Cue Biopharma (NASDAQ:CUE) shareholders doesn't alleviate pain of five-year loss - Simply Wall St
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Cue Biopharma CEO to Present Clinical Updates at Piper Sandler Healthcare Conference | CUE Stock News - StockTitan
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates - MSN
Cue Biopharma, Inc. (NASDAQ:CUE) Shares Purchased by GSA Capital Partners LLP - Defense World
Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Cue Biopharma’s Nasdaq Compliance Struggle: Risks and Implications for Future Stability - MSN
Jefferies cuts Cue Biopharma shares target, retains buy rating on potential - Investing.com UK
Cue Biopharma earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Cue Biopharma Inc (CUE) Quarterly 10-Q Report - Quartzy
Cue names Daniel Baker interim CDO, CSO Anish Suri to transition to advisor role - MSN
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Cue Biopharma Reports Increased Revenue Amid Ongoing Losses - TipRanks
Cue Biopharma Inc (CUE) Q3 2024 Earnings: EPS of $0.17 Beats Est - GuruFocus.com
Cue Biopharma's Cancer Drug Shows 91% Survival Rate in Phase 1 Trial, Revenue Up 57% | CUE Stock News - StockTitan
Cue Biopharma Announces Strategic Organizational Transition - GlobeNewswire
Cue Biopharma Strengthens Leadership: J&J Veteran with 15+ Drug Approvals Joins as CDO | CUE Stock News - StockTitan
Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus reshapes outlook - Investing.com Australia
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference - The Manila Times
Cue Biopharma to Present Latest Clinical Trial Data at Stifel Healthcare Conference | CUE Stock News - StockTitan
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting - The Manila Times
Cue Biopharma Presents Positive Updated Data from its Phase - GlobeNewswire
Cue Biopharma Cancer Drug Trial Soars: 91% Survival Rate, Shatters Expectations | CUE Stock News - StockTitan
Ballard Power Systems Inc (BLDP-T) QuotePress Release - The Globe and Mail
Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update - MarketBeat
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Cue Biopharma authorizes more shares By Investing.com - Investing.com Australia
Cue Biopharma authorizes more shares - Investing.com India
Cue Biopharma Inc (CUE) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):